R. Scott Obach

R. Scott Obach publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where R. Scott Obach sits on this spectrum.

R. Scott Obach D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where R. Scott Obach sits on this spectrum.

Best Publications

• An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19.

  Dafydd R. Owen;Charlotte M. N. Allerton;Annaliesa S. Anderson;Lisa Aschenbrenner

  1454
  Citations

• The conduct of in vitro and in vivo drug-drug interaction studies: A Pharmaceutical Research and Manufacturers of America (PhRMA) perspective

  Thorir D. Bjornsson;John T. Callaghan;Heidi J. Einolf;Volker Fischer

  922
  Citations

• A comprehensive listing of bioactivation pathways of organic functional groups.

  Amit S. Kalgutkar;Iain Gardner;R. Scott Obach;Christopher L. Shaffer

  700
  Citations

• Validated assays for human cytochrome P450 activities.

  Robert L. Walsky;R. Scott Obach

  694
  Citations

• Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions.

  R. Scott Obach;Robert L. Walsky;Karthik Venkatakrishnan

  611
  Citations

• Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.

  R. Scott Obach;Franco Lombardo;Nigel J. Waters

  567
  Citations

• Managing the challenge of chemically reactive metabolites in drug development

  B. Kevin Park;Alan Boobis;Stephen Clarke;Chris E P Goldring

  517
  Citations

• THE IMPACT OF P-GLYCOPROTEIN ON THE DISPOSITION OF DRUGS TARGETED FOR INDICATIONS OF THE CENTRAL NERVOUS SYSTEM: EVALUATION USING THE MDR1A/ 1B KNOCKOUT MOUSE MODEL

  Angela Doran;R. Scott Obach;Bill J. Smith;Natilie A. Hosea

  514
  Citations

• The Utility of in Vitro Cytochrome P450 Inhibition Data in the Prediction of Drug-Drug Interactions

  R. Scott Obach;Robert L. Walsky;Karthik Venkatakrishnan;Emily A. Gaman

  500
  Citations

• Aldehyde oxidase: an enzyme of emerging importance in drug discovery.

  David C. Pryde;Deepak Dalvie;Qiyue Hu;Peter Jones

  447
  Citations

• Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine

  Kirk M. Bertelsen;Karthik Venkatakrishnan;Lisa L. von Moltke;R. Scott Obach

  369
  Citations

• Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions.

  Amit S. Kalgutkar;R. Scott Obach;Tristan S. Maurer

  348
  Citations

• Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose.

  R. Scott Obach;Amit S. Kalgutkar;John R. Soglia;Sabrina X. Zhao

  294
  Citations

• Chemical and Computational Methods for the Characterization of Covalent Reactive Groups for the Prospective Design of Irreversible Inhibitors

  Mark E. Flanagan;Joseph A. Abramite;Dennis P. Anderson;Ann Aulabaugh

  293
  Citations

• What is the Objective of the Mass Balance Study? A Retrospective Analysis of Data in Animal and Human Excretion Studies Employing Radiolabeled Drugs

  Sarah J. Roffey;R. Scott Obach;Jenny I. Gedge;Dennis A. Smith

  292
  Citations

• Physicochemical Space for Optimum Oral Bioavailability: Contribution of Human Intestinal Absorption and First-Pass Elimination

  Manthena V S Varma;R Scott Obach;Charles Rotter;Howard R Miller

  290
  Citations

• METABOLISM AND DISPOSITION OF VARENICLINE, A SELECTIVE α4β2 ACETYLCHOLINE RECEPTOR PARTIAL AGONIST, IN VIVO AND IN VITRO

  R. Scott Obach;Anne E. Reed-Hagen;Suzanne S. Krueger;Beth J. Obach

  283
  Citations

• Comparison of Different Algorithms for Predicting Clinical Drug-Drug Interactions, Based on the Use of CYP3A4 in Vitro Data: Predictions of Compounds as Precipitants of Interaction

  Odette A. Fahmi;Susan Hurst;David Plowchalk;Jack Cook

  275
  Citations

• SERTRALINE IS METABOLIZED BY MULTIPLE CYTOCHROME P450 ENZYMES, MONOAMINE OXIDASES, AND GLUCURONYL TRANSFERASES IN HUMAN: AN IN VITRO STUDY

  R. Scott Obach;Loretta M. Cox;Larry M. Tremaine

  256
  Citations

• Measurement of michaelis constants for cytochrome P450-mediated biotransformation reactions using a substrate depletion approach

  R. Scott Obach;Anne E. Reed-Hagen

  253
  Citations